Skip to main content
G2GBIO, Inc. logo

G2GBIO, Inc. — Investor Relations & Filings

Ticker · 456160 ISIN · KR7456160001 KO Manufacturing
Open in API
Filings indexed 89 across all filing types
Latest filing 2026-03-19 Major Shareholding Noti…
Country KR South Korea
Listing KO 456160

About G2GBIO, Inc.

https://www.g2gbio.com/

G2GBIO, Inc. is a biotechnology company specializing in sustained-release pharmaceuticals through its proprietary drug delivery system platform. The company's core technology, InnoLAMP (Innovative Long-Acting MicroParticle), is used to develop long-acting injectable microspheres that provide a controlled, extended release of therapeutic agents. This platform aims to improve treatment efficacy and patient compliance for chronic diseases by reducing dosing frequency. G2GBIO's research and development pipeline is focused on creating long-acting formulations for conditions including Alzheimer's disease, Type 2 diabetes, schizophrenia, and post-operative pain. The company also develops specialized applications for targeted drug delivery in areas such as oncology.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under Article 147 of the Capital Markets Act. This document details the shareholding status of major shareholders and their special relations, including changes in ownership, purpose of holding (management influence), and specific details of the reporting entity and special relations. This fits the definition of a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant share ownership levels.
2026-03-19 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 9th fiscal year (2025) of G2GBIO, Inc. It contains comprehensive financial statements, management discussion and analysis, board information, and operational details. This is the standard Korean regulatory filing equivalent to a 10-K, which provides a full annual overview of the company's performance and financial status. FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal announcement of the submission of an audit report (감사보고서 제출) by the company G2G Bio. It provides a summary of the audit opinion, key financial figures, and capital impairment status as required by regulatory disclosure rules in Korea. It is not the full audit report itself, but rather a regulatory filing announcing the completion and submission of the audit, which fits the definition of a Report Publication Announcement (RPA). FY 2025
2026-03-18 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is a short announcement regarding the scheduling and details of an Investor Relations (IR) event (Corporate Day). It provides the date, time, location, and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it fits the criteria for a regulatory notification of an upcoming corporate event, it is classified as a Regulatory Filing (RNS).
2026-03-17 Korean
[기재정정]투자판단관련주요경영사항 (장기지속형 미세구체 약물전달 기술 플랫폼 공동연구 및 기술이전계약 체결)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (G2G Bio) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a specific business event: the signing of a joint research and technology transfer agreement (licensing-out) for a drug delivery platform. This type of disclosure, which reports significant corporate events or material developments that do not fit into specific categories like M&A or financial reports, is classified as a general regulatory filing (RNS) in the provided schema.
2026-03-16 Korean
[기재정정]투자판단관련주요경영사항 (장기지속형 미세구체 약물전달 기술 플랫폼 공동연구 및 기술이전계약 체결)
Management Reports Classification · 98% confidence The document is a regulatory filing from a Korean company (G2G Bio) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically detailing a technology transfer and joint research agreement. It includes a correction notice (정정신고) for the contract terms. Since this document describes a specific business transaction (licensing/partnership) and does not fit into the specific categories of M&A (which usually refers to corporate takeovers/mergers) or other specialized categories, it falls under the general regulatory filing category for material corporate events.
2026-03-16 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.